Table 1. Intensive immunosuppression... | American Society of Hematology

Table 1.

Intensive immunosuppression (ATG plus cyclosporine) for severe aplastic anemia

Study	N	Median age, y	Response, %	Relapse, %	Clonal evolution, %	Survival, %
German⁶⁸	84	32	65	19	8	58 at 11 y
EGMBT⁶⁹	100	16	77	12	11	87 at 5 y
NIH⁷⁰	122	35	61	35	11	55 at 7 y
Japan^*⁷¹	119	9	68	22	6	88 at 3 y
NIH†⁷²	104	30	62	37	9	80 at 4 y

Study	N	Median age, y	Response, %	Relapse, %	Clonal evolution, %	Survival, %
German⁶⁸	84	32	65	19	8	58 at 11 y
EGMBT⁶⁹	100	16	77	12	11	87 at 5 y
NIH⁷⁰	122	35	61	35	11	55 at 7 y
Japan^*⁷¹	119	9	68	22	6	88 at 3 y
NIH†⁷²	104	30	62	37	9	80 at 4 y

Only studies of more than 20 enrolled patients are tabulated. Responses to immunosuppressive therapy are usually partial; blood counts may not become normal but transfusions are no longer required and the neutrophil count is adequate to prevent infection. Relapse is usually responsive to further immunosuppressive therapies. Clonal evolution is to dysplastic bone marrow changes and/or cytogenetic abnormalities. For details, see “Immunosuppression”

With androgens and ± G-CSF

†

With mycophenolate mofetil

View Large

This Feature Is Available To Subscribers Only